Effects of xamoterol in acute myocardial infarction

blood pressure, heart rate, arrhythmias and early clinical course

J. McMurray, C. C. Lang, D. MacLean, A. D. Struthers, D. G. McDevitt

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Xamoterol is a novel partial agonist of ß1 adrenoceptors that reduces myocardial ischaemia and improves ventricular function in patients with mild to moderate heart failure. In a double blind, randomised, placebo controlled study, the effects of xamoterol given in a dose of 200 mg twice daily were studied in 51 consecutive patients with acute myocardial infarction, including 17 receiving diuretics for left ventricular failure. Treatment was started on the third day of admission and continued for 7 days. Blood pressure was recorded at 0900 daily, and 24 hour ambulatory electrocardiogram monitoring was commenced at this time on days 1 (pre-treatment), 4, 6 and 9 of admission. Additional drug therapy was recorded daily throughout the study. One patient died prior to randomisation and three were withdrawn (1 placebo, 2 xamoterol) with ventricular arrhythmias and/or disturbances of conduction. Compared to placebo, xamoterol had no effect on the rate of ventricular premature beats or ventricular tachycardia. Xamoterol increased nocturnal heart rate (0000-0600 hrs 79 ± 2; placebo 72 ± beats/min; P<0.03) but did not change blood pressure. Three patients receiving xamoterol, and 7 on placebo, required new (after randomisation) antianginal therapy. One patient treated with placebo developed new heart failure. These results show that xamoterol can be administered safely to selected patients following myocardial infarction, including those treated for mild heart failure.

    Original languageEnglish
    Pages (from-to)295-303
    Number of pages9
    JournalInternational journal of cardiology
    Volume31
    Issue number3
    DOIs
    Publication statusPublished - Jun 1991

    Fingerprint

    Xamoterol
    Cardiac Arrhythmias
    Heart Rate
    Myocardial Infarction
    Blood Pressure
    Placebos
    Heart Failure
    Random Allocation
    Ambulatory Monitoring
    Ventricular Premature Complexes
    Ventricular Function
    Ventricular Tachycardia
    Diuretics
    Adrenergic Receptors
    Myocardial Ischemia
    Electrocardiography
    Therapeutics
    Drug Therapy

    Cite this

    @article{d37c6944961e4346aa9282724cc1db4c,
    title = "Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course",
    abstract = "Xamoterol is a novel partial agonist of {\ss}1 adrenoceptors that reduces myocardial ischaemia and improves ventricular function in patients with mild to moderate heart failure. In a double blind, randomised, placebo controlled study, the effects of xamoterol given in a dose of 200 mg twice daily were studied in 51 consecutive patients with acute myocardial infarction, including 17 receiving diuretics for left ventricular failure. Treatment was started on the third day of admission and continued for 7 days. Blood pressure was recorded at 0900 daily, and 24 hour ambulatory electrocardiogram monitoring was commenced at this time on days 1 (pre-treatment), 4, 6 and 9 of admission. Additional drug therapy was recorded daily throughout the study. One patient died prior to randomisation and three were withdrawn (1 placebo, 2 xamoterol) with ventricular arrhythmias and/or disturbances of conduction. Compared to placebo, xamoterol had no effect on the rate of ventricular premature beats or ventricular tachycardia. Xamoterol increased nocturnal heart rate (0000-0600 hrs 79 ± 2; placebo 72 ± beats/min; P<0.03) but did not change blood pressure. Three patients receiving xamoterol, and 7 on placebo, required new (after randomisation) antianginal therapy. One patient treated with placebo developed new heart failure. These results show that xamoterol can be administered safely to selected patients following myocardial infarction, including those treated for mild heart failure.",
    author = "J. McMurray and Lang, {C. C.} and D. MacLean and Struthers, {A. D.} and McDevitt, {D. G.}",
    year = "1991",
    month = "6",
    doi = "10.1016/0167-5273(91)90380-8",
    language = "English",
    volume = "31",
    pages = "295--303",
    journal = "International journal of cardiology",
    issn = "0167-5273",
    publisher = "Elsevier",
    number = "3",

    }

    Effects of xamoterol in acute myocardial infarction : blood pressure, heart rate, arrhythmias and early clinical course. / McMurray, J.; Lang, C. C.; MacLean, D.; Struthers, A. D.; McDevitt, D. G.

    In: International journal of cardiology, Vol. 31, No. 3, 06.1991, p. 295-303.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Effects of xamoterol in acute myocardial infarction

    T2 - blood pressure, heart rate, arrhythmias and early clinical course

    AU - McMurray, J.

    AU - Lang, C. C.

    AU - MacLean, D.

    AU - Struthers, A. D.

    AU - McDevitt, D. G.

    PY - 1991/6

    Y1 - 1991/6

    N2 - Xamoterol is a novel partial agonist of ß1 adrenoceptors that reduces myocardial ischaemia and improves ventricular function in patients with mild to moderate heart failure. In a double blind, randomised, placebo controlled study, the effects of xamoterol given in a dose of 200 mg twice daily were studied in 51 consecutive patients with acute myocardial infarction, including 17 receiving diuretics for left ventricular failure. Treatment was started on the third day of admission and continued for 7 days. Blood pressure was recorded at 0900 daily, and 24 hour ambulatory electrocardiogram monitoring was commenced at this time on days 1 (pre-treatment), 4, 6 and 9 of admission. Additional drug therapy was recorded daily throughout the study. One patient died prior to randomisation and three were withdrawn (1 placebo, 2 xamoterol) with ventricular arrhythmias and/or disturbances of conduction. Compared to placebo, xamoterol had no effect on the rate of ventricular premature beats or ventricular tachycardia. Xamoterol increased nocturnal heart rate (0000-0600 hrs 79 ± 2; placebo 72 ± beats/min; P<0.03) but did not change blood pressure. Three patients receiving xamoterol, and 7 on placebo, required new (after randomisation) antianginal therapy. One patient treated with placebo developed new heart failure. These results show that xamoterol can be administered safely to selected patients following myocardial infarction, including those treated for mild heart failure.

    AB - Xamoterol is a novel partial agonist of ß1 adrenoceptors that reduces myocardial ischaemia and improves ventricular function in patients with mild to moderate heart failure. In a double blind, randomised, placebo controlled study, the effects of xamoterol given in a dose of 200 mg twice daily were studied in 51 consecutive patients with acute myocardial infarction, including 17 receiving diuretics for left ventricular failure. Treatment was started on the third day of admission and continued for 7 days. Blood pressure was recorded at 0900 daily, and 24 hour ambulatory electrocardiogram monitoring was commenced at this time on days 1 (pre-treatment), 4, 6 and 9 of admission. Additional drug therapy was recorded daily throughout the study. One patient died prior to randomisation and three were withdrawn (1 placebo, 2 xamoterol) with ventricular arrhythmias and/or disturbances of conduction. Compared to placebo, xamoterol had no effect on the rate of ventricular premature beats or ventricular tachycardia. Xamoterol increased nocturnal heart rate (0000-0600 hrs 79 ± 2; placebo 72 ± beats/min; P<0.03) but did not change blood pressure. Three patients receiving xamoterol, and 7 on placebo, required new (after randomisation) antianginal therapy. One patient treated with placebo developed new heart failure. These results show that xamoterol can be administered safely to selected patients following myocardial infarction, including those treated for mild heart failure.

    U2 - 10.1016/0167-5273(91)90380-8

    DO - 10.1016/0167-5273(91)90380-8

    M3 - Article

    VL - 31

    SP - 295

    EP - 303

    JO - International journal of cardiology

    JF - International journal of cardiology

    SN - 0167-5273

    IS - 3

    ER -